Moglia A, Sinforiani E, Zandrini C, Gualtieri S, Corsico R, Arrigo A
Clin Neuropharmacol. 1986;9 Suppl 3:S73-8.
Oxiracetam is a new psychotropic drug that has been shown to positively affect processes both in animals and in patients with impaired brain function. The aim of this study was the evaluation of the effects of oxiracetam treatment on clinical symptoms in 43 patients with organic brain syndrome (OBS). After a 2-week washout period, patients were assigned to either oxiracetam or placebo, according to a randomized, double-blind, between-patients design. Both oxiracetam and placebo were orally given bid for 8 weeks; daily dose of oxiracetam was 2 X 800 mg. In OBS patients with a mild to moderate degree of cognitive impairment, oxiracetam showed to improve cognitive functions, logical performance, and attention. Other behavioral and functional parameters were also positively modified.
奥拉西坦是一种新型精神药物，已证明其对动物及脑功能受损患者的各项机能均有积极影响。本研究旨在评估奥拉西坦治疗对43例器质性脑综合征（OBS）患者临床症状的影响。经过2周的洗脱期后，根据随机、双盲、患者间对照设计，将患者分为奥拉西坦组或安慰剂组。奥拉西坦和安慰剂均每日口服两次，持续8周；奥拉西坦的日剂量为2×800毫克。在轻度至中度认知障碍的OBS患者中，奥拉西坦显示出可改善认知功能、逻辑能力和注意力。其他行为和功能参数也得到了积极改善。
